4SC gets Phase IIa boost
This article was originally published in Scrip
Executive Summary
Shareholders responded positively to preliminary Phase IIa data unveiled by 4SC, the German drug discovery company, relating to its lead autoimmune compound vidofludimus, an oral inhibitor of interleukin-17 (IL-17) release, in inflammatory bowel disease (IBD). The company reported that the exploratory, open-label, single-arm Phase IIa ENTRANCE study met its primary endpoint of significantly increasing the response rate in corticosteroid-dependent IBD patients to 88.5% against an average placebo response across published benchmark clinical trials of approximately 20%.